Acute lymphocytic leukaemia+1
Not yet recruitingA study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.
A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.
- Disease:Acute lymphocytic leukaemiaAcute lymphocytic leukaemia recurrent
- Substances:BlinatumomabCyclophosphamide+5
The Netherlands- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Blinatumomab
- Sponsor:Amgen Inc.









